Plasma thrombin-activatable fi brinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients

References

• LibbyP, TherouxP.Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481–8.
   Google Scholar
• Hamsten A, Wiman B, de Faire U, Blomb8ck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator inhibitor in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557–63.
   Google Scholar
• Undas A, Szuldrzynski K, Stepien E, Zalewski J, Godlewski J, TraczW, Pasowicz M, Zmudka K. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008; 196: 551–7.
   Google Scholar
• -lassies D, Merce Roqué M, MonteagudoJ, Martorell T, Sionis A, Arzamendi D, Heras M, Reverter JC. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome. Thrombosis Research 2009; 124: 614–8.
   Google Scholar
• Wang W, Boffa PB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273:27176–81.
   Google Scholar
• Zhao L, MorserJ, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998; 80: 949–55.
   Google Scholar
• Brouwers GJ, Vos HL, Leebeek FW, Bulk 5, Schneider M, Boffa M, Koschinsky M, van Tilburg NH, Nesheim ME, Berlina RM, Gómez Garcia EB. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98:1992–3.
   Google Scholar
• Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I. Identification of polymorphisms in the promoter and the 3’ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97:2053–8.
   Google Scholar
• Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M.Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277:1021–30.
   Google Scholar
• Boffa MB, Koschinsky ML Curiouser and curiouser: recent advances in measurementof thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40:431–42.
   Google Scholar
• Myles T, Nishimura T, Yun TH, Nagashima M, MorserJ, Patterson AJ, Ronald G, Pearl RG, Leung LK. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059–67.
   Google Scholar
• Fogg DK, Bridges DE, Cheung KK, Kassam G, Filipenko NR, Choi KS, Fitzpatrick SL, Nesheim M, Waisman DM.The p11 subunit of annexin II heterotetramer is regulated by basic carboxypeptidase. Biochemistry 2002; 41: 4953–61.
   Google Scholar
• Christofferson RD. Manual of cardiovascular medicine, chapter 1: Acute myocardial infarction. Edited by Griffin BP, Topol EJ; Lippincott Williams &Wilkins. 3rd edition, 2009, p. 1-28.
   Google Scholar
• Connolly HM, Oh JK.Chapter 14-Echocardiography, in Braunwald’s Heart Disease:A Textbook of Cardiovascular Medicine, Edited by Libby P. Bonow RO, Mann DL, Zipes DP; Saunders Elsevier. 8th edition, 2008, p.227-314.
   Google Scholar
• Trinder P. Enzymatic colorimetric test. Ann Clin Biochem 1969; 6: 24.
   Google Scholar
• Onaka L. Lipids.In Clinical chemistry concepts and applications. Edited by Anderson SC, Cockayne S. London: W.B. Saunders, 1993.
   Google Scholar
• Livak KJ. Allelic discrimination using fluorogenic probes and the 5’ nuclease assay. GenetAnal 1999, 14: 143–9.
   Google Scholar
• Ladenvall C. Genetic association studies in stroke. Doctoral thesis from the Institute of Neuroscience and Physiology, the Sahlgrenska Academy at G8teborg University, G8teborg, Sweden 2008.
   Google Scholar
• Meltzer ME, Doggen OM, de Groot PG, Meijers JCM, Rosendaal FR, Lisman T. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 2009; 94:811–8.
   Google Scholar
• Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, FerrieresJ, Amouyel P. Evans A, Ducimetiere P. Cambien F, Tiret L, Juhan-Vague I; Prime Study Group. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME study. J Thromb Haemost 2005; 3: 1503–10.
   Google Scholar
• Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegàrd A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamstzen A, Humphries SE; HIFMECH Study Group. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867–73.
   Google Scholar
• Santamaria A, Martinez-Rubio A, Borrell M, Mateo J, Ortín R, Fontcuberta J.Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 2004; 89: 880–1.
   Google Scholar
• Folkeringa N, Coppens M, Veeger NJ, Bom VJ, Middeldorp 5, Hamulyak K, Prins MH, Bailer HR, van der Meer. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Thromb Haemost 2008; 100: 38–44.
   Google Scholar
• Cellai AP, Antonucci E, Liotta AA, Fedi 5, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb Res 2006; 118:495–500.
   Google Scholar
• Gils A, Alessi MC, Browers E, Peeters M, Marx P. LeursJ, Bouma B, Hendriks D, Juhan-Vague I, Declerck P. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122–7.
   Google Scholar
• Guimaffies AHC, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124: 659–65.
   Google Scholar
• Tregouet D, Schnabel R, Alessi M, Godefroy T, Declerck P. Nicaud V. Munzel T, Bickel C, Rupprecht HJ, Lubos E, Zeller T, Juhan-Vague I, Blankenberg 5, Tiret L, Morange PE; AtheroGene Investigators. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death inpatients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2009, 7:49–57.
   Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868–74.
   Google Scholar
• Marx PF, Lisman T, Adelmeijer J, Marquart J, Meijers JCM.Binding of TAFI to collagen: a role for TAFI inthe regulation of platelet adhesion?J Thromb Haemost 2006; 4 (Suppl 1): 208.
   Google Scholar